When the tumor dies faster than the kidney can clear it
Tumor lysis syndrome
Effective therapy can kill a large, fast-dividing cancer so abruptly that the cells spill their contents into the blood — potassium, phosphate, and a flood of purines that becomes uric acid — and the two crystals that result, urate and calcium-phosphate, clog and poison the tubules: a metabolic emergency that is largely preventable with hydration, rasburicase, and, for venetoclax, a deliberately slow dose ramp-up.
- 30.7%
- TLS in high-risk patientsShare of a prospective cohort of 153 high-risk haematology patients (acute leukaemia, aggressive NHL, Burkitt) who developed tumor lysis syndrome — laboratory TLS in 11.1%, clinical TLS with AKI in 19.6%
- ~33%
- developed AKIAbout one third of that high-risk cohort developed acute kidney injury, for which TLS was an independent risk factor; TLS was also associated with higher day-90 mortality (OR 2.45)
- 4 hours
- to urate control with rasburicaseTime to plasma uric-acid control in hyperuricaemic adults with rasburicase versus 27 hours with allopurinol, in a phase III randomized trial
- 2.1%
- clinical TLS with ramp-upClinical TLS in 239 CLL patients started on venetoclax with the mandated dose ramp-up (VeRVe real-world study) — none were fatal and none caused renal failure
- 13%
- lab TLS in routine practiceLaboratory TLS in relapsed-CLL patients on venetoclax in routine practice (6 of 48) — higher than the 3–6% seen in clinical trials
Teaching case · illustrative composite, not a real patient
A 68-year-old man with bulky, high-count chronic lymphocytic leukemia (white cell count 190,000, palpable splenomegaly, del(17p)) is started on venetoclax with the standard weekly dose ramp-up, hydration, and allopurinol. Forty-eight hours after the first escalation, routine labs show potassium 5.9 mmol/L, phosphate 6.4 mg/dL, uric acid 9.8 mg/dL, calcium 7.6 mg/dL, and a creatinine risen from 1.0 to 1.7 mg/dL.
The rising potassium, phosphate, and urate with a falling calcium and a creatinine bump two days into venetoclax escalation are recognized as laboratory tumor lysis syndrome tipping into clinical TLS. The next venetoclax dose is held, intravenous fluids are intensified to restore urine flow, and rasburicase is given to convert the uric acid to soluble allantoin (G6PD status having been checked first). Potassium and phosphate are managed; routine urinary alkalinization is avoided because it worsens calcium-phosphate precipitation. The metabolic derangements correct over the next day or two, renal function recovers, and venetoclax is cautiously resumed under closer monitoring once the labs normalize.
Teaching point — Tumor lysis syndrome is a treatment complication, not a direct drug toxin: a large, chemosensitive tumor burden lysed quickly releases potassium, phosphate, and purines faster than the kidney can excrete them, and the resulting uric-acid and calcium-phosphate crystals injure the tubules. It is defined by laboratory criteria (the electrolyte storm) and clinical criteria (organ dysfunction, chiefly AKI). The whole game is prevention: risk-stratify, hydrate everyone, give rasburicase to the high-risk, and — for venetoclax specifically — respect the mandated dose ramp-up, which keeps clinical TLS around 2% even in real-world practice. Avoid urinary alkalinization; it trades urate solubility for calcium-phosphate deposition.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
How we learned it
- 2001
Goldman et al. randomize 52 children at high risk for tumor lysis to rasburicase versus allopurinol: rasburicase gave 2.6-fold less uric-acid exposure and an 86% versus 12% drop in urate by 4 hours.
Established recombinant urate oxidase as dramatically faster than allopurinol at clearing uric acid in children.
PMID 11342423 - 2010
Cortes et al. extend the rasburicase evidence to adults in a phase III trial: urate control in 87% with rasburicase versus 66% with allopurinol, and control within 4 hours versus 27 hours in hyperuricaemic patients.
Confirmed rasburicase's speed and efficacy in adults, cementing it as first-line for high-risk and hyperuricaemic patients.
PMID 20713865 - 2011
Howard, Jones, and Pui publish the definitive review of tumor lysis syndrome — unifying the pathophysiology, the laboratory-versus-clinical definitions, and risk-stratified prophylaxis.
Became the reference framework for recognizing, grading, and preventing TLS across pediatric and adult oncology.
PMID 21561350 - 2013
Darmon et al. prospectively follow 153 high-risk haematology patients in the rasburicase era: TLS occurred in 30.7%, one third developed AKI, admission phosphate independently predicted clinical TLS, and TLS was associated with higher day-90 mortality.
Showed that even with modern prophylaxis, TLS remains a common driver of AKI and death in high-risk patients — and pointed to phosphate, not just urate, as central.
PMID 23772757 - 2024
The real-world VeRVe study (Schwaner et al.) follows 239 CLL patients on venetoclax with the mandated dose ramp-up: clinical TLS in only 2.1%, none fatal and none causing renal failure.
Demonstrated that a deliberate dose-escalation schedule with risk-based prophylaxis controls the TLS risk of a highly active oral agent in everyday practice.
PMID 38421404
The landmark studies
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era
Darmon M, et al. · Br J Haematol 2013 · PMID 23772757
TLS remained common despite prophylaxis and was an independent risk factor for AKI; admission phosphate predicted clinical TLS and TLS was associated with higher mortality.
TLS 30.7%; laboratory TLS 11.1%; clinical TLS with AKI 19.6%; AKI in ~1/3; day-90 mortality OR 2.45 (1.09–5.50)
Control of plasma uric acid in adults at risk for TLS: rasburicase vs rasburicase-then-allopurinol vs allopurinol (phase III)
Cortes J, et al. · J Clin Oncol 2010 · PMID 20713865
Rasburicase controlled plasma uric acid more rapidly and more often than allopurinol in adults at risk for TLS, including the high-risk and hyperuricaemic subgroups.
Urate response 87% (rasburicase) vs 78% (sequential) vs 66% (allopurinol); high-risk 89% vs 68%; time to control 4 h vs 27 h
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
Goldman SC, et al. · Blood 2001 · PMID 11342423
Rasburicase produced faster and deeper urate reduction than allopurinol during induction, with no detectable anti-rasburicase antibodies at day 14.
Uric-acid AUC0–96 128 vs 329 mg/dL·h (2.6-fold less exposure); 4-hour urate reduction 86% vs 12%
Low incidence of TLS in elderly CLL patients treated with venetoclax under real-world conditions (VeRVe)
Schwaner I, et al. · Ann Hematol 2024 · PMID 38421404
With the mandated dose ramp-up and risk-based prophylaxis, clinical TLS was uncommon and never caused renal failure or death in routine venetoclax use.
Clinical TLS 2.1% (5/239); laboratory TLS 6.3% (15/239); no TLS deaths, no renal failure; median age 73
What the data says now
How disproportionately each agent's FAERS reports name these phenotypes vs. all other drugs (reporting odds ratio; significant signals only, 95% CI lower bound > 1; as of 2026-07-10). A reporting signal, not incidence or proven causation.
| Agent | XTAL | LYTE |
|---|---|---|
| Cytarabine | Cytarabine, Crystal / Obstructive Nephropathy: no significant signal | Cytarabine, Electrolyte Disturbance: ROR 2.41, 1,313 reports |
How it's managed
- 1
Risk-stratify, then hydrate everyone
Assess TLS risk from tumor burden, proliferation rate (LDH, white count), and baseline renal function; give aggressive isotonic IV hydration to all but the lowest risk to maintain high urine flow. Match urate-lowering to risk — allopurinol for low/intermediate, rasburicase up front for high risk.
Definitive review — risk-stratified prophylaxis framework · PMID 21561350
- 2
Rasburicase for high risk or established hyperuricemia
Recombinant urate oxidase converts uric acid to soluble allantoin, controlling urate within hours where allopurinol (which only blocks new urate formation) takes about a day. Check G6PD status first — rasburicase causes hemolysis and methemoglobinemia in G6PD deficiency.
Phase III RCT — urate control 87% vs 66%, 4 h vs 27 h · PMID 20713865
- 3
For venetoclax, the dose ramp-up is the prophylaxis
The mandated weekly dose escalation — with risk-based hydration, urate-lowering, and scheduled lab monitoring during each step-up — is what keeps clinical TLS around 2% and off dialysis even in real-world CLL. Hold the next dose if labs signal evolving TLS.
Real-world VeRVe cohort — clinical TLS 2.1%, no renal failure · PMID 38421404
- 4
Treat the electrolytes and the kidney — and skip alkalinization
Manage hyperkalemia and hyperphosphatemia, correct symptomatic hypocalcemia cautiously, and use renal replacement therapy for refractory metabolic derangement or oliguric AKI. Do not routinely alkalinize the urine — it improves urate solubility but promotes calcium-phosphate precipitation, trading one crystal for another.
Definitive review — management framework, alkalinization no longer recommended · PMID 21561350
What the guidelines say
Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.